Prostate Cancer - Results from #26780

Mechanisms of persistent activation of the androgen receptor in CRPC: Recent advances and future perspectives - Abstract November 10, 2011

Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: Recent developments - Abstract November 10, 2011

Highly sensitive molecular diagnosis of prostate cancer using surplus material washed off from biopsy needles - Abstract November 10, 2011

Sense and nonsense of an extended pelvic lymph node dissection in prostate cancer - Abstract November 10, 2011

Radical prostatectomy: An option for high-risk prostate cancer - Abstract November 10, 2011

The effect of 6 and 15 MV on intensity-modulated radiation therapy prostate cancer treatment: Plan evaluation, tumour control probability and normal tissue complication probability analysis, and the theoretical risk of secondary induced malignancies - Abs November 10, 2011

Magnetic resonance tomography-guided interventional procedure for diagnosis of prostate cancer - Abstract November 10, 2011

Selective detection of histologically aggressive prostate cancer: An Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial - Abstract November 9, 2011

Localising prostate cancer: Comparison of endorectal magnetic resonance (MR) imaging and 3D-MR spectroscopic imaging with transrectal ultrasound-guided biopsy - Abstract November 9, 2011

Learning image context for segmentation of prostate in CT-guided radiotherapy - Abstract November 9, 2011

Adaptive energy selective active contour with shape priors for nuclear segmentation and gleason grading of prostate cancer - Abstract November 9, 2011

Racial disparities in changing to a high-volume urologist among men with localized prostate cancer - Abstract November 9, 2011

Prostate cancer in the elderly: Frequency of advanced disease at presentation and disease-specific mortality - Abstract November 9, 2011

A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: A University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study - Abstract November 9, 2011

Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy - Abstract November 9, 2011

Geographic and outcome variation among black men diagnosed with prostate cancer - Abstract November 8, 2011

Health-related quality of life after radical retropubic prostatectomy and permanent prostate brachytherapy: A 3-year follow-up study - Abstract November 8, 2011

Characterising the castration-resistant prostate cancer population: A systematic review - Abstract November 8, 2011

Can sexual bother after radical prostatectomy be predicted preoperatively? Findings from a prospective national study of the relation between sexual function, activity and bother - Abstract November 8, 2011

Among potent men post radical prostatectomy, does the need for phosphodiesterase inhibitors have an impact on sexual bother scores? - Abstract November 8, 2011

Page 1340 of 1435